STOCK TITAN
  1. Home
  2. News
  3. AIM

AIM ImmunoTech Inc. - AIM STOCK NEWS

Welcome to our dedicated page for AIM ImmunoTech news (Ticker: AIM), a resource for investors and traders seeking the latest updates and insights on AIM ImmunoTech stock.

AIM ImmunoTech Inc. (NYSE American: AIM) is a pioneering immuno-pharma company based in Ocala, Florida, focused on the research and development of innovative therapeutics aimed at treating a variety of cancers, immune disorders, and viral diseases including COVID-19. The company's flagship product is Ampligen® (rintatolimod), a first-in-class investigational drug that acts as a highly selective TLR3 agonist immuno-modulator with broad-spectrum activity. Ampligen is currently undergoing extensive clinical trials targeting globally important cancers and viral diseases.

AIM ImmunoTech's product portfolio also includes Alferon N Injection, an injectable formulation of natural alpha interferon used to treat a specific category of genital warts, a sexually transmitted disease. Ampligen has shown promising results in the treatment of chronic fatigue syndrome and is being developed for other indications like hepatitis B, HIV, and several cancer types, including renal cell carcinoma, malignant melanoma, non-small cell lung cancer, ovarian cancer, breast cancer, colorectal cancer, urothelial cancer, prostate cancer, and pancreatic cancer.

In recent developments, AIM ImmunoTech announced positive top-line interim data indicating that the combination of Ampligen with Keytruda (pembrolizumab) could be significantly more effective than pembrolizumab alone in treating recurrent ovarian cancer. The company is also working on various clinical trials, including studies for treating post-COVID conditions and long COVID, led by renowned medical experts like Dr. Charles Lapp.

AIM ImmunoTech has formed strategic research agreements with prominent institutions such as the Japanese National Institute of Infectious Diseases and Shionogi & Co., Ltd., exploring the potential of Ampligen as an adjuvant therapy for COVID-19. The company continues to focus on operational execution and has successfully completed cGMP manufacturing of over 9,000 clinical vials of Ampligen, which is crucial for its ongoing and upcoming clinical trials.

The company's leadership team, headed by CEO Thomas K. Equels, is committed to advancing its pipeline and achieving clinical and commercial success. AIM ImmunoTech engages with its stakeholders through regular updates and CEO Corner segments, providing insights into its clinical programs and financial performance, ensuring transparency and fostering investor confidence.

For more detailed information, visit the official website and connect with AIM ImmunoTech on social media platforms such as X, LinkedIn, and Facebook.

News

Kellner Seeking Expedited Appeal of Delaware Court Finding that Nomination Notice was Properly Denied

Rhea-AI Summary
Court Found that Several AIM Advance Notice Bylaws Are Invalid. The Delaware Court of Chancery ruled in favor of the Kellner Group, finding four separate advance notice bylaw provisions adopted by AIM Immunotech Inc. to be invalid. However, the Court also found that Mr. Kellner's notice of nominations did not comply with certain remaining advance notice provisions. AIM announced that it will disregard the Kellner Group's nominations, and any proxies voted in favor of the Kellner Group nominees will not be recognized or tabulated at the Annual Meeting.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News

Delaware Court Rules in Favor of AIM ImmunoTech and Upholds Board’s Determination that Activist Group’s Nominations Are Invalid

Rhea-AI Summary
AIM ImmunoTech Inc. (NYSE American: AIM) announced the Delaware Court of Chancery ruled against the Activist Group's nomination notice, finding it invalid under the Company's Bylaws. The Court upheld the Board's decision to reject the notice due to omissions and misleading information. AIM will reconvene its 2023 Annual Meeting and adjourn until January 5th, disregarding any proxies submitted by the Activist Group. The Board urges shareholders to vote for all four Company Directors on the WHITE Proxy Card.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.33%
Tags
none
-
News

AIM ImmunoTech Provides Update Regarding Annual Meeting

Rhea-AI Summary
AIM ImmunoTech Inc. (NYSE American: AIM) will convene its 2023 Annual Meeting of Stockholders on December 1st, adjourning until December 29th to await a ruling from the Delaware Court of Chancery regarding litigation brought against the Company and its directors by an Activist Group seeking to nominate three candidates for election to AIM's Board of Directors. The Board has determined the Activist Group's nomination notice as invalid and will disregard any proxies or votes cast for the individuals on the Activist Group's proxy card unless the litigation results in a finding that the Notice is valid. The record date for determining shareholders eligible to vote at the 2023 Annual Meeting remains October 2, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.82%
Tags
none
News

AIM ImmunoTech Bolsters Intellectual Property Estate for Ampligen® with Issuance of Two Key U.S. Patents

Rhea-AI Summary
AIM ImmunoTech Inc. (AIM) extends exclusive U.S. rights to Ampligen for cancer and ME/CFS through 2039 with the issuance of U.S. patents No. 11,813,279 and 11,813,281. The patents cover novel methods for cancer therapy and improving exercise tolerance in ME/CFS patients. AIM's CEO, Thomas K. Equels, emphasizes the potential financial future of the company and the driving force behind multiple clinical studies in oncology, ME/CFS, and Post-COVID conditions.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News

AIM ImmunoTech Completes Treatment of Last Subject in Phase 2 Study Evaluating Ampligen® for the Treatment of Post-COVID Conditions

Rhea-AI Summary
AIM ImmunoTech Inc. (AIM) announced the completion of dosing in the Phase 2 study for Ampligen® as a potential therapeutic for Post-COVID fatigue. No severe adverse events reported. Topline data expected in Q1 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.44%
Tags
clinical trial covid-19
-
News

Kellner Group Urges Stockholders of AIM Immunotech to Vote Gold Card Now for Desperately Needed Change

Rhea-AI Summary
AIM Immunotech Inc. (NYSE American: AIM) - The Kellner Group urges stockholders to act against the entrenched Board's reckless spending and self-interested behavior. The Board has wasted $15 million in the past two years to prevent stockholders from voting on Board nominations and has failed to engage in dialogue to avoid this destructive and wasteful path. The Kellner Group, owning 6.5% of outstanding shares, is fully aligned with stockholders and brings the skills, experience, and credibility necessary for AIM to succeed.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
News

AIM ImmunoTech Reports Third Quarter 2023 Financial Results and Provides Clinical Pipeline Update

Rhea-AI Summary
AIM ImmunoTech Inc. (NYSE American: AIM) reported financial results for Q3 2023 and provided a business update, highlighting progress in the Ampligen® clinical development programs. The company aims to achieve value-driving milestones in ovarian and pancreatic cancer programs. Recent highlights include encouraging translational data from an ongoing Phase 2 clinical trial in ovarian cancer and engaging a business development consulting firm to partner pipeline programs. Financially, AIM reported $22.4 million in cash, with increasing R&D and G&A expenses. The company will host a conference call and webcast on November 15, 2023, to discuss operational and financial results.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.44%
Tags
earnings
-
News

AIM ImmunoTech Announces Publication of Data from Roswell Park Comprehensive Cancer Center Phase 1 Study Evaluating Ampligen® as a Component of a Chemokine-Modulating (CKM) Regimen in Metastatic Triple-Negative Breast Cancer

Rhea-AI Summary
AIM ImmunoTech Inc. (NYSE American: AIM) announces the publication of results from the Phase 1 study at Roswell Park Comprehensive Cancer Center in patients with metastatic triple-negative breast cancer using chemokine modulation therapy. The study evaluated the safety and the combination's ability to promote local CTL influx to mTNBC lesions. The data were published in The Journal for ImmunoTherapy of Cancer.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.27%
Tags
clinical trial
-
News

AIM ImmunoTech to Discuss Third Quarter 2023 Financial Results on November 15, 2023 and Host Conference Call and Webcast

Rhea-AI Summary
AIM ImmunoTech Inc. (AIM) to host conference call to discuss Q3 2023 operational and financial results. Interested participants and investors can access the call and webcast on November 15, 2023. The call will feature AIM's CEO and Scientific Officer, providing insights into the company's performance and future prospects.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.51%
Tags
earnings
News

AIM ImmunoTech Announces Encouraging Translational Data from Phase 2 Study Evaluating Ampligen® for the Treatment of Advanced Recurrent Ovarian Cancer

Rhea-AI Summary
AIM ImmunoTech Inc. (NYSE American: AIM) announced encouraging translational data from an ongoing Phase 2 clinical trial utilizing AIM’s drug Ampligen® in patients with platinum-sensitive advanced recurrent ovarian cancer. The data highlights the effectiveness of combinatorial treatments including Ampligen in modulating the cellular make-up of the tumor microenvironment through cytokine profile changes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.17%
Tags
clinical trial

FAQ

What is the current stock price of AIM ImmunoTech (AIM)?

The current stock price of AIM ImmunoTech (AIM) is $0.207 as of December 4, 2024.

What is the market cap of AIM ImmunoTech (AIM)?

The market cap of AIM ImmunoTech (AIM) is approximately 13.2M.

What is AIM ImmunoTech's main focus?

AIM ImmunoTech focuses on developing therapeutics to treat various cancers, immune disorders, and viral diseases, including COVID-19.

What are AIM ImmunoTech's key products?

The company's key products include Ampligen (rintatolimod), a TLR3 agonist immuno-modulator for cancer and viral diseases, and Alferon N Injection for treating genital warts.

What recent achievements has AIM ImmunoTech made?

Recent achievements include positive interim data for Ampligen combined with Keytruda in ovarian cancer treatment, and the successful manufacturing of over 9,000 clinical vials of Ampligen.

Who are AIM ImmunoTech's notable partners?

AIM ImmunoTech has research agreements with the Japanese National Institute of Infectious Diseases and Shionogi & Co., Ltd. for developing Ampligen as a COVID-19 therapy.

What clinical trials is AIM ImmunoTech currently conducting?

The company is conducting clinical trials for various cancers, chronic fatigue syndrome, and COVID-19 related conditions.

How can investors access AIM ImmunoTech's financial reports?

Investors can access financial reports on AIM ImmunoTech's official website and the U.S. Securities and Exchange Commission (SEC) filings.

How does AIM ImmunoTech engage with its stakeholders?

AIM ImmunoTech engages stakeholders through regular updates, CEO Corner segments, and social media platforms like X, LinkedIn, and Facebook.

What is the significance of Ampligen in AIM ImmunoTech's portfolio?

Ampligen is a cornerstone of AIM ImmunoTech's portfolio, showing broad-spectrum activity in clinical trials for cancers, viral diseases, and immune disorders.

Who leads AIM ImmunoTech?

The company is led by CEO Thomas K. Equels, who focuses on advancing the company's pipeline and achieving clinical and commercial success.

Where can more information about AIM ImmunoTech be found?

More information can be found on the company's official website, aimimmuno.com, and its social media channels.

Stock AIM logo
AIM ImmunoTech Inc.

NYSE:AIM

AIM Rankings

#5488 Ranked by Market Cap
N/A Ranked by Dividends

AIM Stock Data

13.19M
57.95M
8.57%
14.08%
0.77%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States of America
OCALA